Related Experiment Video
Updated: Jan 26, 2026
07:10
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
22.6K
Countdown to 2030: eliminating hepatitis B disease, China
Jue Liu1, Wannian Liang2, Wenzhan Jing1
1Department of Epidemiology and Biostatistics, School of Public Health, Peking University, No.38, Xueyuan Road, Haidian District, Beijing 100191, China.
Bulletin of the World Health Organization
|April 18, 2019
Summary
China has reduced hepatitis B virus (HBV) incidence through vaccination but needs to prioritize diagnosis and treatment to meet 2030 elimination goals. Key actions include enhancing medical capabilities and reducing patient costs.
Area of Science:
- Hepatology
- Public Health
- Infectious Diseases
Background:
- Hepatitis B virus (HBV) infection poses a significant global health challenge, with China bearing the largest burden.
- China has achieved substantial reductions in HBV incidence over three decades, primarily through high vaccination coverage.
- Despite progress, China faces challenges in meeting the 2030 target for a 65% reduction in hepatitis B mortality.
Purpose of the Study:
- To outline priorities for HBV elimination in China by 2030, aligning with the WHO Global Health Sector Strategy on Viral Hepatitis.
- To identify key areas for action to reduce hepatitis B mortality and achieve elimination targets.
Main Methods:
- Analysis of current HBV control strategies in China.
- Review of WHO targets for viral hepatitis elimination.
- Identification of gaps and recommendations for improving HBV diagnosis and treatment services.
Main Results:
- High vaccination coverage (>95%) has been successful in reducing HBV incidence.
- Significant gaps remain in the diagnosis and treatment of HBV infection.
- Existing national programs require better coordination for an integrated approach.
Conclusions:
- Prioritizing diagnosis and treatment services is crucial for reducing HBV mortality in China.
- Enhancing diagnostic and treatment capabilities of healthcare providers is essential.
- Reducing patient financial burdens and establishing integrated prevention and control systems are vital for HBV elimination by 2030.
Related Concept Videos
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
267
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
267
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
222
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
222
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
190
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
190
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
221
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
221
01:17Kinetics of Drug Elimination
4.1K
Eliminating drugs from the body is a vital process that occurs through excretion or metabolism. Understanding the kinetics of drug elimination is crucial for drug development, dosage determination, and optimizing patient outcomes.
Drug clearance depends on the rate of drug elimination and its plasma concentration. Another important parameter is the half-life of a drug, which is the time required for its concentration to decrease by half. In most cases, drug clearance follows first-order...
Drug clearance depends on the rate of drug elimination and its plasma concentration. Another important parameter is the half-life of a drug, which is the time required for its concentration to decrease by half. In most cases, drug clearance follows first-order...
4.1K
01:26Enhanced Elimination of Poison
881
Poison can be effectively removed from the gastrointestinal (GI) tract through various decontamination procedures.
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
881